Meritage Pharma is committed to the development of prescription products based on safe and effective molecules for the treatment of gastrointestinal and atopic diseases. Meritage Pharma’s initial product candidate is intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the esophagus.

Patents show all

45Applications12Issued

Clinical Trials show all

1Phase 2

SEC Filings show all

D3

Contact Information


    SEC Form D Funding Events

    DateOfferedSoldType
    2011-11-16$7,500,002$6,500,002Equity
    2009-08-27$29,972,053$29,972,053Equity
    2008-12-15UnknownUnknownOther (Paper Filing)

    Key Executives

    • Elaine M. Phillips, Ph.D.
      Executive Officer, Director
    • Cam L. Garner
      Director
    • James C. Blair, Ph.D.
      Director
    • Kenneth J. Widder, M.D.
      Director
    • Adam K. Simpson
      Executive Officer
    • Malcolm R. Hill
      Executive Officer